KDR and neoplasm: Sorafenib inhibits several tyrosine kinases, including VEGFR, platelet-derived growth factor receptor (PDGFR), c-Kit, and Flt3, suppressing tumor cell proliferation, inducing apoptosis, and mitigating tumor angiogenesis [300].